ERBB2 and breast cancer: In HER2-positive BC, HER3 overexpression results in tamoxifen resistance [65] and is associated with resistance to fulvestrant [66] and paclitaxel, whereas inhibiting HER3 overexpression restores drug sensitivity [67].